Our long-term programmatic goal is to develop screening strategies to diagnose asymptomatic pancreaticcancer (PaC). Up to 80% of PaCs have hyperglycemia and diabetes (DM), which is evident many monthsprior to the cancer diagnosis and improves following resection of PaC. Conversely, older subjects with newonsetDM have a ~8 fold higher risk of having PaC compared to the general population. Recognition ofnew-onset DM as an early manifestation of PaC could lead to diagnosis of asymptomatic early stagePaC. In this proposal we take our strong and consistent clinical and epidemiological observations to thelaboratory to understand the pathogenesis of PaC-associated DM (PaCDM) and identify its biomarkers.
Specific Aim 1 : To determine if B-cell dysfunction is an early and key defect in PaCDM: DM occurs ininsulin resistant states when B-cells fail to compensate for impaired insulin action. The very high prevalenceof DM in PaC implies high rate of B-cell failure. We have developed a technique in humans to simultaneouslyassess B-cell function, insulin sensitivity, and hepatic insulin extraction using 3 radiolabeled glucose tracers.We have used this technique to study subjects with type 2 DM, impaired glucose tolerance and normalglucose tolerance. We will perform similar studies in PaC to determine if B-cell dysfunction is an early andkey defect in glucose metabolism in PaCDM.
Specific Aim 2 : To determine if adrenomedullin (AM) is themediator of PaCDM: AM is a 52 amino acid peptide hormone expressed in normal human islets that inhibitsinsulin exocytosis from B-cells. It is markedly overexpressed in PaC and its plasma levels are increased inPaCDM. We hypothesize thai AM is the mediator of B-cell dysfunction in PaC. In preliminary studies wehave been able to
|Chini, Claudia C S; Espindola-Netto, Jair M; Mondal, Gourish et al. (2016) SIRT1-Activating Compounds (STAC) Negatively Regulate Pancreatic Cancer Cell Growth and Viability Through a SIRT1 Lysosomal-Dependent Pathway. Clin Cancer Res 22:2496-507|
|Murphy, Stephen J; Hart, Steven N; Halling, Geoffrey C et al. (2016) Integrated Genomic Analysis of Pancreatic Ductal Adenocarcinomas Reveals Genomic Rearrangement Events as Significant Drivers of Disease. Cancer Res 76:749-61|
|Chaiteerakij, Roongruedee; Petersen, Gloria M; Bamlet, William R et al. (2016) Metformin Use and Survival of Patients With Pancreatic Cancer: A Cautionary Lesson. J Clin Oncol 34:1898-904|
|Cao, H; Eppinga, R D; Razidlo, G L et al. (2016) Stromal fibroblasts facilitate cancer cell invasion by a novel invadopodia-independent matrix degradation process. Oncogene 35:1099-110|
|Hu, Chunling; Hart, Steven N; Bamlet, William R et al. (2016) Prevalence of Pathogenic Mutations in Cancer Predisposition Genes among Pancreatic Cancer Patients. Cancer Epidemiol Biomarkers Prev 25:207-11|
|McWilliams, Robert R; Maisonneuve, Patrick; Bamlet, William R et al. (2016) Risk Factors for Early-Onset and Very-Early-Onset Pancreatic Adenocarcinoma: A Pancreatic Cancer Case-Control Consortium (PanC4) Analysis. Pancreas 45:311-6|
|Carr, Ryan M; Fernandez-Zapico, Martin E (2016) Pancreatic cancer microenvironment, to target or not to target? EMBO Mol Med 8:80-2|
|Wang, Jianbo; Galvao, Joana; Beach, Krista M et al. (2016) Novel Roles and Mechanism for KrÃ¼ppel-like Factor 16 (KLF16) Regulation of Neurite Outgrowth and Ephrin Receptor A5 (EphA5) Expression in Retinal Ganglion Cells. J Biol Chem 291:18084-95|
|Lopez, Angelica P; Kugelman, Jeffrey R; Garcia-Rivera, Jose et al. (2016) The Structure-Specific Recognition Protein 1 Associates with Lens Epithelium-Derived Growth Factor Proteins and Modulates HIV-1 Replication. J Mol Biol 428:2814-31|
|Lakshminarayanan, Vani; Supekar, Nitin T; Wei, Jie et al. (2016) MUC1 Vaccines, Comprised of Glycosylated or Non-Glycosylated Peptides or Tumor-Derived MUC1, Can Circumvent Immunoediting to Control Tumor Growth in MUC1 Transgenic Mice. PLoS One 11:e0145920|
Showing the most recent 10 out of 242 publications